Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Phase 1

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 1(4)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Role: lead

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Role: lead

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Role: collaborator

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Role: lead

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Role: lead

All 5 trials loaded